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SNIP/p140Cap mRNA expression is an unfavourable prognostic
factor in breast cancer and is not expressed in normal breast tissue
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The prevalence and clinical relevance of SNIP/p140Cap has not been extensively investigated. Here SNIP/p140Cap mRNA
expression was studied in 103 breast tumour biopsies, where it was detected in B37% of tumour specimens, but not in any normal
breast specimens. Expression correlated significantly with unfavourable overall survival. This suggests that SNIP/p140Cap may be a
useful diagnostic and prognostic marker for breast cancer and its expression in breast cancer, but not in normal breast tissue, suggests
that it may have potential as a therapeutic target.
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Synaptosome-associated protein of 25kDa (SNAP-25) was initially
described as a neuronal membrane protein essential for neurite
outgrowth and synaptic vesicle exocytosis (Chin et al, 2000).
SNAP25-interacting protein (ie, SNIP), originally described as
selectively expressed in the brain and co-distributed with SNAP-
25, is tightly associated with the brain cytoskeleton and may serve
as a linker protein connecting SNAP-25 to the submembranous
cytoskeleton, where it is involved in regulating neurosecretion
(Chin et al, 2000). Although NCBI described the human form of
this transcript as homo sapiens SNAP-interacting protein (SNIP)
mRNA (NM_025248), in general the rat form is described as SNIP
(NP_062251), the mouse form as p140 (NP_061361), and sequence
homology data suggest the human form to be the recently
identified p130cas-associated protein, p140Cap (Di Stefano et al,
2004).
p130Cas, encoded by the BCAR1 gene (van der Flier et al, 2001),
is a signalling molecule involved in the linkage of actin
cytoskeleton to the extracellular matrix during cell migration, cell
invasion and transformation (Cabodi et al, 2004). Upon integrin
engagement, p130Cas is tyrosine-phosphorylated and its presence
has been shown to be required for integrin-dependent activation of
epidermal growth factor receptor. It has been established that
patients with primary breast tumours expressing a high level of
p130Cas/BCAR1 protein, experience more rapid disease recurrence
and are at a higher risk for intrinsic resistance to tamoxifen
therapy (van der Flier et al, 2000; Cabodi et al, 2004). Transgenic
mice overexpressing p130Cas in the mammary gland have been
found to have extensive mammary epithelial hyperplasia, asso-
ciated with activation of Src kinase, extracellular signal-regulated
kinase 1/2, mitogen-activated protein kinase and Akt pathways,
resulting in increased rates of proliferation and decreased
apoptosis (Cabodi et al, 2006). Further evidence for the involve-
ment of p130Cas in breast cancer include studies downregulating
p130Cas expression with siRNA in her2-expressing cells that
results in apoptosis, indicating p130Cas to be involved in cell
survival. Immunohistochemical analysis of 150 human breast
tumours indicated p130Cas overexpression in a high percentage of
cases, independent of tumour histology type or grade (Cabodi
et al, 2006).
Analysis of p140Cap, the p130CAS-associated protein (homo
sapiens SNIP), has been limited to date. Immunoblotting studies
indicated p140Cap expression in a range of cell lines, including
human ECV304, T47 and HeLa, as well as rat FRT and murine
N1E115 cells. Expression of p140Cap in NIH3T3 and ECV304 cells
is reported to inhibit early phases of cell spreading on fibronectin.
p140Cap involvement in integrin- and growth factor-mediated
signalling, modulating the ability of cells to spread on matrix
proteins, is proposed to be associated with p130Cas and actin
stress fibres (Di Stefano et al, 2004). Western blot studies of adult
mouse primary tissues indicate p140Cap expression in brain, testis
and epithelial-rich tissues including lung, kidney and mammary
glands (Di Stefano et al, 2004).
Here we report the first study of SNIP/p140Cap (SNIP) mRNA
expression in a large bank of human specimens of any kind. We
describe expression of this transcript in a retrospective series of
103 primary breast carcinomas and 19 normal breast tissue
specimens, and we report how its presence is associated with
outcome for breast cancer patients.
MATERIALS AND METHODS
Patients
Tissue specimens from 103 cases of primary breast cancers
procured (snap-frozen within 30min of procurement) during
1993–1997 at St Vincent’s University Hospital, Dublin, were
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sincluded in this study. A number of clinical and pathologic
parameters were abstracted from patients’ charts including details
on age, postoperative treatment and follow-up, tumour stage, and
hormonal analysis. Tumours were typed, graded and staged as
previously described. Nineteen noncancerous breast biopsies were
also included in these studies to represent normal breast tissue.
RNA extraction
Total RNA was isolated from all specimens using TriReagent
(Sigma, Poole, England). RNA quantity and quality were assessed
using a Nanodrop (ND-1000; Labtech International, East Sussex,
UK) and an Agilent bioanalyser (Agilent 2100; Agilent Technologies,
Santa Clara, CA, USA), respectively.
cDNA formation on mRNA template
Following priming with oligo(dT) at 651C for 5min, followed by 1-
min incubation on ice, cDNA was synthesised from 100ng total
RNA, using Superscript III RNase H-RNase OUT Ribonuclease
(Invitrogen Biosciences Ltd., Dun Laoighare, Dublin) and a
cocktail of dNTPs, by incubating at 501C for 1h, followed by
701C for 15min, in a 40ml reaction volume.
Quantitative reverse-transcriptase PCR
The cDNA (diluted 1:10) was amplified in 25ml reactions by
quantitative reverse-transcriptase PCR (qPCR), using an ABI 7500
Real-Time PCR System (Applied Biosystems, Foster City, CA,
USA). Following evaluation of 11 potential endogenous controls in
a random selection of 14 breast specimens (seven breast tumours
and seven normal breast specimens), this study involved evalua-
tion of SNIP/p140Cap mRNA in all 103 breast carcinomas and 19
normal breast specimens, in triplicate. Primers and TaqMan
probes were designed using Primer Express Software 2.0, based on
criteria applied by us in previous studies (Doolan et al, 2008).
Primer and probe sequences for SNIP/p140Cap amplification were
forward primer, 50-AGACGCATCGTGCAACCTATG-30; reverse
primer, 50-TGGCTGCGTCTCGGTATAGC-30; probe, TCCAACCGC
ACAGGGCAGGGT. The profile of all reactions was 501C for 2min,
951C for 10min, 40 cycles of 951C and 601C for 1min. Analysis
including all components except cDNA (replaced with H2O)
showed no contamination of reaction components. In addition,
controls including RNA, but lacking reverse transcriptase enzyme
and oligo(dT), respectively, verified no DNA/pseudogene contam-
ination of starting material. SNIP/p140Cap threshold cycle (CT)
results were subsequently normalised to two suitable endogenous
controls – b-actin and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) – and calibrated against a pooled cDNA from breast
specimens, using the comparative CT method, 2
 DDCT (Livak and
Schmittgen, 2001).
Statistical analysis
Statistical (univariate and multivariate) analyses of the results were
performed using SPSS 12.1. The data were censored at 5 years for
multivariate analysis. A value of Po0.05 was considered statisti-
cally significant.
RESULTS
Patient characteristics
The 103 consenting patients whose tumour biopsies (procured
prior to any treatment with tamoxifen or chemotherapeutic
agents) were included in this study were aged between 31 and 90
years at the time of diagnosis (mean age¼58 years). Twenty-six
women were o50 years and 77 were X50 years of age at diagnosis.
Tumours ranged from 0.6 to 8.0cm (mean¼2.8cm). Eighteen
tumours were T1; 82 tumours were T2 and three tumours were T3.
Eighty-one tumours were invasive ductal carcinoma, 17 were
invasive lobular and five were tumours of special type (two tubular
and three mucinous). Eleven tumours were grade 1; 31 were grade
2; and 53 were grade 3. Sixty-six tumours were ER
þ and 44 were
ER
 . Oestrogen receptor status was not available for three patients.
Forty-five tumours had no axillary metastases, whereas 58 had
metastasised to axillary lymph nodes.
Sixty-nine women were treated with postoperative tamoxifen;
25 did not receive tamoxifen. Forty-nine patients were treated
with adjuvant systemic chemotherapy (CMFþ/ adriamycin); 45
patients did not receive chemotherapy. Details regarding tamoxifen
and systemic chemotherapy were not available for nine patients.
Maximal follow-up was 3026 days with a mean follow-up of 1887
days.
Quantitative reverse-transcriptase PCR
Analysis for 11 potential endogenous controls in a random
selection of 14 (seven tumour; seven normal) specimens indicated
18S, b2-microglobin, b-actin and GAPDH mRNAs to be expressed
at similar levels in all specimens analysed. b-actin and GAPDH
were subsequently selected for amplification in all specimens, in
parallel with SNIP/p140Cap, and the mean of their CT values was
used for normalisation.
Detection of SNIP/p140Cap mRNA
SNIP/p140Cap mRNA was detected in 36.9% (38/103) of the breast
tumour specimens analysed and was found not to be expressed in
any of the normal breast specimens.
Prognostic relevance of SNIP/p140Cap
The prognostic relevance of SNIP/p140Cap expression at diagnosis
was evaluated in relation to relapse/disease-free survival (RFS) and
overall survival (OS).
In relation to RFS, Cox univariate analysis of RFS (Table 1)
indicated that expression of SNIP/p140Cap transcript did not
associate with RFS, whereas tumour size (P¼0.009) and grade
(P¼o0.0005), treatment with adjuvant chemotherapy (P¼0.002),
lymph-node status (Po0.0005) and ER status (P¼0.004) showed
significant correlation with RFS. These results were supported by
Kaplan–Meier analysis (Table 1), indicating ER positivity to be a
favourable factor (P¼0.0032), with increased tumour size
(P¼0.007), advanced grade (P¼0.0013), treatment with adjuvant
chemotherapy (P¼0.0012) and spread to lymph nodes
(Po0.00005) to correlate with bad prognosis.
Chi-squared analysis indicated a significant association between
SNIp/P140Cap mRNA expression and tumour size (P¼0.02) and
tamoxifen therapy (P¼0.037) (see Table 2). No other significant
associations were found between expression of SNIP/p140Cap
and age at diagnosis, tumour grade, tumour type, treatment with
adjuvant chemotherapy, lymph-node status or ER status. By
multivariate analysis (Table 3), the most important prognostic
factors for RFS were found to be spread of cancer to lymph nodes
(Po0.0005), ER status (P¼0.001), tumour size (P¼0.011) and
tumour grade (P¼0.045). Kaplan–Meier analysis indicated no
correlation between RFS and expression of SNIP/p140Cap mRNA
(Figure 1A).
Univariate Cox analysis (Table 1) indicated that the factors
investigated in this study that were significant prognostic
indicators of OS were SNIP/p140Cap mRNA expression
(P¼0.037), tumour size (P¼0.048), tumour grade (Po0.0005),
tumour type (P¼0.031) and lymph-node status (P¼0.001).
Expression of ER was strongly associated with OS; however,
statistical significance was not reached (P¼0.056). These results
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p140Cap expression (P¼0.0327), increased tumour size (0.0437),
tumour type (invasive ductal) (P¼0.0453), advanced stage of
tumours (P¼0.0003), adjuvant chemotherapy (P¼0.0457) and
spread to lymph nodes (P¼0.0006) to be significantly correlated
with poor prognosis. No significant association was found between
OS and age at diagnosis or adjuvant tamoxifen treatment.
Multivariate analysis (Table 3) indicated lymph-node status
(P¼0.003), tumour grade (P¼0.017) and SNIP/p140Cap mRNA
expression (P¼0.005) to be independent prognostic factors for
OS. The unfavourable association of SNIP/p140Cap mRNA
expression (P¼0.0327) with outcome for patients, indicated by
Kaplan–Meier analysis, is shown in Figure 1A.
Predictive relevance of SNIP/p140Cap expression
To establish if expression of SNIP/p140Cap mRNA is predictive
of response to adjuvant chemotherapy, Kaplan–Meier analysis
was performed on those cases only where chemotherapy was
administered. As indicated in Figure 1B, the results of this analysis
suggest SNIP/p140Cap expression not to be predictive of outcome
in terms of either RFS or OS. Interestingly, analysis of cases where
chemotherapy was not administered indicated SNIP/p140Cap
mRNA expression to be associated with poor outcome for patients
in terms of both RFS (P¼0.0355) and OS (P¼0.0216) (Figure 1C).
DISCUSSION
This study represents the first reported analysis of SNIP/p140Cap
expression and relevance to patients’ outcome in cancer. SNIP/
p140Cap mRNA was detected in approximately 37% of the breast
tumours analysed, and its expression was significantly associated
with increased tumour size. Although an association was not found
between expression of SNIP/p140Cap mRNA and RFS, a significant
association was evident between expression of this transcript and
disease outcome, in terms of OS, with the presence of SNIP/
p140Cap mRNA associated with shorter survival from diagnosis.
Indeed, multivariate analysis indicates that, similar to advanced
Table 2 Correlation between clinicopathological factors and expression
of SNIP mRNA in breast carcinoma
Characteristics No. of cases
SNIP
(absent vs present) (%) P
Age (years)
o50 8/26 30.8 0.454
450 30/77 39.0
Tumour size
o2.8cm 15/56 26.8 0.020*
42.8cm 23/47 48.9
Lymph-node metastasis
Negative 17/45 37.8 0.870
Positive 21/58 36.2
Histology grade
I 6/11 54.5 0.347
II 12/39 30.8
III 20/53 37.7
Histology type
IDC 32/81 39.5 0.458
ILC 4/17 23.5
Special 2/5 40.0
ER status
Negative 13/34 38.2 0.738
Positive 23/66 34.8
Chemotherapy
No 19/45 42.2 0.242
Yes 15/49 30.6
Tamoxifen
No 5/25 20.0 0.037*
Yes 30/69 43.5
IDC¼invasive ductal carcinoma; ILC¼invasive lobular carcinoma; SNIP¼SNAP25-
interacting protein. *Significant parameter. P-values from w
2 analyses.
Table 1 Univariate Cox analysis supported by Kaplan–Meier analysis
Overall survival (OS) Relapse-free survival (RFS)
Characteristics P
a P
b P
a P
b
Age (o50 vs X50 years.) 0.964 0.9636 0.263 0.2599
Tumour size (o2.8 vs X2.8cm) 0.048* 0.0437* 0.009* 0.007*
Lymph-node metastasis (negative vs positive) 0.001* 0.0006* o0.0005* o0.00005*
Histology grade (I and II vs III) o0.0005* 0.0003* o0.0005* 0.0013*
Histology type (IDC vs ILC vs special) 0.031* 0.0453* 0.206 0.0624
ER status (negative vs positive) 0.056 0.0514 0.004* 0.0032*
Chemotherapy (yes vs no) 0.050 0.0457* 0.002* 0.0012*
Tamoxifen (yes vs no) 0.449 0.4475 0.182 0.1784
SNIP (absent vs present) 0.037* 0.0327* 0.473 0.4716
IDC¼invasive ductal carcinoma; ILC¼invasive lobular carcinoma; SNIP¼SNAP25-interacting protein. *Significant parameter. Mean size (2.8cm) was used as cutoff; grades I
and II grouped together vs grade III. Kaplan–Meier analysis supports the univariate Cox regression studies, indicating ER positivity to be associated with favourable prognosis
whereas expression of SNIP mRNA, increased tumour size, tumour type, advanced grade, spread to nodes and adjuvant chemotherapy treatment are associated with poor
outcome for patients.
aCox regression P-value.
bKaplan–Meier P-value.
Table 3 Multivariate Cox regression backward stepwise (likelihood
ratio)
Characteristics
Overall
survival (OS)
Relapse-free
survival (RFS)
PP
Lymph node (spread vs no spread) 0.003 o0.0005
ER (absence vs presence) NS 0.001
Histology grade (I and II vs III) 0.017 0.045
Tumour size (o2.8 vs X2.8cm) NS 0.011
SNIP mRNA (absence vs presence) 0.005 NS
NS¼not significant; SNIP¼SNAP25-interacting protein. Parameters in the multi-
variate analysis included age, tumour size, tumour grade, lymph-node status, ER status,
as well as SNIP mRNA expression. Mean size (2.8cm) was used as cutoff; grade I and
II grouped together vs grade III. This table summarises significant factors.
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stumour grades and spread of cancer to lymph nodes, SNIP/
p140Cap mRNA expression is an independent unfavourable
prognostic factor for OS. Whether or not the in vivo effects of
SNIP/p140Cap are due to its interactions with p130Cas is yet to be
determined. However, unfavourable associations between p130Cas
expression and breast cancer recurrence and resistance to
tamoxifen (van der Flier et al, 2000, 2001) and our identification
(as described here) of SNIP/p140Cap in breast tumours – but not
in normal breast tissue – and its association with larger tumours
and shorter survival times from diagnosis, suggest that its effects
may, at least in part, be due to an involvement with p130Cas.
The results from this study were further analysed to investigate a
potential predictive relevance for SNIP/p140Cap. Although a
significant association was not found between expression of this
transcript and outcome for patients who received adjuvant
chemotherapy, we identified the presence of SNIP/p140Cap to be
associated with unfavourable outcome, in terms of both RFS and
OS, for patients who did not receive chemotherapy.
These novel findings suggest that SNIP/p140Cap analysis by
qPCR may have potential as both a diagnostic and a prognostic
biomarker study for breast cancer. Its expression in breast
tumours, but not in normal tissue, suggests that it may have
potential as a therapeutic target.
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Figure 1 (A) Kaplan–Meier survival curves for SNIP mRNA presence or absence and its association with disease/relapse-free survival (RFS) and overall
survival (OS), respectively. A significant unfavourable association was found between expression of SNIP mRNA and OS. (B) SNAP25-interacting protein
expression did not show a significant association with RFS and OS, respectively, for patients who received adjuvant chemotherapy, but (C) showed
significant association with RFS and OS, respectively, for patients who did not receive adjuvant chemotherapy.
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